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Abstract
Cadherin is an adhesion molecule and a superfamily of 
calcium-mediated membrane glycoproteins. E-cadherin is 
the prototype of the class E-cadherin that links to caten-
ins to form the cytoskeleton. Recent evidence has shown 
that E-cadherin not only acts as an adhesive, but also 
plays important roles in growth development and carci-
nogenesis. It has been recently viewed as an invasion 
as well as a growth suppressor gene. This review sum-
marizes the recent discoveries on E-cadherin and its role 
in gastric cancer. In particular, our work on E-cadherin 
in gastric cancer, including its relation with Helicobacter 
pylori  and clinical applications, are described in detail.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Although decreasing in incidence, gastric cancer remains a 
major medical problem and is the second most common 
fatal cancer worldwide. In spite of  intense interest and 
extensive investigations, its prognosis has not been 
improved significantly in recent years. The dramatic 
variations in the incidence of  gastric cancer in different 
geographic areas and from one generation to the next have 
led to the hypothesis that the incidence of  gastric cancer 
is determined largely by environmental rather than genetic 
factors. The identification and the subsequent classification 
of  Helicobacter pylori (H pylori) infection as type I carcinogen 
by the WHO sparked a significant understanding in the 
etiology of  gastric cancer. The current discovery of  
germline mutation at E-cadherin gene in familial gastric 
cancers and the findings of  IL-1 polymorphisms with 
increased gastric cancer risk again turn the focus towards 
the studying of  host genetics. The molecular studies of  the 
host may give a definite proof  of  the etiological role of  H 
pylori in inducing gastric carcinoma.
Only a small fraction of  all cancers arise in individuals 
who car r y a ger ml ine defect confer r ing genet ic 
predisposition. Nevertheless, many genes that underlie 
inherited cancer syndromes have more widespread roles 
in sporadic cancers, as a result of  somatic mutations that 
arise during tumor initiation or progression. Hence, in this 
review paper, we shall focus on the E-cadherin gene, one 
of  the candidate genes in gastric cancer, and the work we 
have done on E-cadherin in gastric carcinogenesis.
E-CADHERIN
Cadherin is a superfamily of  calcium-mediated membrane 
glycoproteins, with a molecular mass of  120 ku, forming 
one of  the four classes of  adhesion molecules[1-3]. Some 
common cadherins expressed by epithelial cells are 
E-cadherin, N-cadherin and P-cadherin. The intracellular 
domains of  classical cadherins interact with β-catenin, 
γ-catenin (also called plakoglobin) and p120ctn to assemble 
the cytoplasmic cell adhesion complex (CCC) that is 
critical for the formation of  extracellular cell-cell adhesion. 
β-catenin and γ-catenin bind directly to α-catenin, which 
links the CCC to the actin cytoskeleton[4,5]. The cadherins 
are responsible for the homotypic cell-cell adhesion. 
However, knowledge gained in the recent few decades 
has shown that E-cadherin not only acts as an adhesive, 
but also plays important roles in growth development and 
carcinogenesis.
E-CADHERIN AND CANCER
Role of E-cadherin in metastasis
E-cadherin is the prototype of  the cadherin class. It is 
expressed in all epithelial cell types. Underexpression of  
the E-cadherin is found in gastric and other cancers, and 
correlates with infiltrative and metastatic ability[6]. It has 
been proposed that the loss of  E-cadherin-mediated cell-
cell adhesion is a prerequisite for tumor cell invasion and 
metastasis formation[7]. Re-establishing the functional 
cadherin complex, e.g. by forced expression of  E-cadherin, 
results in a reversion from an invasive, mesenchymal, to 
a benign, epithelial phenotype of  cultured tumor cells[7,8]. 
Hence, the E-cadherin gene is also called as an invasion 
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suppressor gene. 
Role of E-cadherin in oncogenesis
Recently, it has been postulated that the role of  E-cadherin 
in carcinogenesis does not limit only to metastasis and in-
vasion (Figure 1). It is now being increasingly recognized 
that there is also a possible role of  E-cadherin in modu-
lating intracellular signaling, and thus promoting tumor 
growth. There are several lines of  evidence. Cadherin-
mediated cell-cell adhesion can affect the Wnt-signaling 
pathway[9,10]. β-catenin (as well as γ-catenin) is usually 
sequestered by cadherins in the cadherin-catenin complex. 
Upon loss of  E-cadherin function, non-sequestered, free 
β-catenin is usually phosphorylated by glycogen synthase 
kinase 3β (GSK-3β) in the adenomatous polyposis coli 
(APC)-axin-GSK-3β complex and subsequently degraded 
by the ubiquitin-proteasome pathway. In many cancer cells, 
loss of  function of  the tumor suppressor APC, mutations 
in β-catenin or inhibition of  GSK-3β by the activated Wnt-
signaling pathway leads to the stabilization of  β-catenin in 
the cytoplasm. Subsequently, it translocates to the nucleus, 
where it binds to the members of  the Tcf/Lef-1 family of  
transcription factors and modulates expression of  Tcf/
Lef-1-target genes, including the proto-oncogene c-myc 
and cyclin D1. In addition, recent studies on familial gas-
tric cancer indicate that E-cadherin can also act at a much 
earlier stage during tumor development. Mutations of  the 
E-cadherin gene were found in three familial gastric cancer 
kindred from New Zealand[11] and this observation was 
confirmed in the kindred of  European origin[12]. These
results demonstrate that loss of  function of  E-cadherin 
may play a role in susceptibility to initial tumor development 
in addition to its role as an inhibitor of  tumor invasion.
EXPRESSION OF E-CADHERIN IN GASTRIC 
CANCER
The expression of  E-cadherin has been studied by 
immunohistochemical method. Decreased expression 
has been observed in gastric cancer by various authors, 
ranging from 17%[13] to 92%[14], depending on the method 
and the definition used. The decreased expression of  
E-cadherin was mainly observed in diffuse type and less 
in intestinal type of  gastric cancer. Direct correlation 
between E-cadherin and the grade of  tumor differentiation 
has been observed in all these studies. In addition, it 
was shown in a study of  413 gastric cancers by Gabbert 
et al.[15] that patients with E-cadherin positive tumors 
had significantly better 3- and 5-year survival rates than 
patients with E-cadherin negative tumors. A similar trend 
of  decrease in disease-free survival was also observed in 
other cancers exhibiting downregulation of  E-cadherin[16].
We have also studied the change in the expression of  the 
E-cadherin complex along the Correa’s cascade in gastric 
cancer by immunohistochemical staining[17]. We observed 
that the staining pattern, intensity and the percentage 
of  cells with positive stains deceased along the Correa’s 
cascade; that is, the staining was strong and membranous 
in normal gastric epithelium, but gradually decreased in 
intensity and percentage, as well as the pattern was changed 
towards cytoplasm in chronic atrophic gastritis, intestinal 
metaplasia, dysplasia and eventually to adenocarcinoma. 
However,  methods to evaluate,  qual i tat ively or 
quantitatively, protein expression in biopsies from human 
tumors may have serious limitations because of  sampling 
from heterogeneous tissue, non-stoichiometric labeling 
and subjective evaluation.
MECHANISM OF INACTIVATION OF 
E-CADHERIN
Genetic inactivation
The E-cadherin gene can be genetically inactivated by a 
number of  mechanisms. The first hit of  a role for E-cad-
herin in tumor development, particularly in suppression 
of  invasion, came from loss of  heterozygosity studies on 
chromosome 16. Subsequently, mutations were reported in 
tumor samples in diffuse type gastric carcinomas[18], gyne-
cologic cancers[19], and infiltrative lobular breast cancer[20,21]. 
In gastric cancer, E-cadherin mutations are common in 
Figure 1  Illustrated interaction between the cadherin–catenin complex and the APC protein. (A) In the absence of Wnt-1 and the 
presence of glycogen synthase kinase (GSK), β-catenin (β-cat) is stabilized and bound to cadherin or APC protein. Cadherin acts 
as a negative regulator of β-catenin by regulating the amount of free β-catenin. The free cytoplasmic β-catenin is degraded. (B) 
In the presence of Wnt-1, GSK is antagonized and mutant APC or tyrosine phosphorylated β-catenin cannot bind to each other, 
cytosolic free β-catenin concentrations rise, which leads to down-stream cell signalling and may be involved in carcinogenesis.
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diffuse type carcinomas, but not seen in intestinal type[18]. 
The specificity of  types of  cancer affected by mutations 
of  the E-cadherin gene, despite the prevalence of  reduced 
E-cadherin expression in many cancer types, suggests that 
E-cadherin mutations may be of  particular importance in 
the development of  these tumors. In addition, mutations 
in diffuse gastric cancer[22] have been detected early in tu-
mor development, suggesting a role in tumor suppression, 
in addition to invasion suppression. Further evidence for 
this comes from the observations that mutations of  E-cad-
herin have also been observed in several kindred exhibiting 
familial gastric cancer[11,12]. Furthermore, at least one kin-
dred exhibited both diffuse gastric cancer and early-onset 
breast cancer[11].
Inactivation by hypermethylation
In recent years, it has become increasingly apparent 
that increased methylation within the promoter regions 
of  genes plays a key role in the inactivation of  many 
important genes during the development of  cancer[23]. 
Subsequently, numerous reports of  E-cadherin promoter 
methylat ion, associated with reduced E-cadherin 
expression, have been published. Hypermethylation at 
E-cadherin has also been shown to play a role in familial 
gastric cancer, acting as the second hit (the first hit is either 
mutation or loss of  heterozygosity) in inactivation of  
E-cadherin[24]. 
We have previously shown that the immunostaining 
of  E-cadherin decreases along the Correa’s cascade; 
therefore, we went on to study the underlying mechanism. 
We found that the frequency of  methylation at E-cadherin 
also increases along the Correa’s cascade, with the highest 
frequency detected in the tumorous lesions and metastatic 
lesions[25]. The methylation frequency correlated with the 
tumor depth and node invasion. In addition, most of  the 
decrease in immunostaining was accounted for by the 
presence of  methylation at E-cadherin. More importantly, 
we also observed that H pylori infection was also associated 
with E-cadherin methylation. 
In fact, the role of  H pylori in the regulation of  
E-cadherin has been studied recently. It has been shown 
that H pylori infection is associated with downregulation 
of  E-cadherin, probably by generating cell signaling events 
that counteract the normal function of  protein kinase 
C[26,27]. The resulting increase in permeability mediated by 
the reduction in cell adhesion might allow H pylori antigens 
to reach the gastric lamina propria and activate the mucosal 
immune system, with resultant tissue damage. 
In relation to the above findings, we therefore hypothe-
sized that by eradicating H pylori, methylation at E-cadherin 
may disappear[28]. We performed a prospective randomized 
trial. Patients with dyspepsia and H pylori infection were 
randomized to receive H pylori eradication therapy (Group 
1, n = 41) or no treatment (Group 2, n = 40) and were fol-
lowed up prospectively. Gastric mucosae were taken for 
methylation assay at week 0 (before treatment) and week 6 
(after treatment). Methylation was assessed using methyla-
tion-specific PCR. Methylation was detected in 46% (19/41) 
and 17% (7/41) at week 0 and 6, respectively in Group 1 
(P = 0.004). 78.9% (15/19) specimens turned unmethyl-
ated after eradicating H pylori. Methylation was detected 
in 47.5% (19/40) and 52.5% (21/40) at weeks 0 and 6, 
respectively in Group 2 (P = 0.5). Archived specimens with 
intestinal metaplasia with H pylori infection (n = 22) and 
without the infection (n = 19) were also retrieved for meth-
ylation analysis. But methylation frequency did not differ 
in H pylori positive or negative intestinal metaplastic speci-
mens (72.7% vs. 63%, P = 0.5). Therefore, we postulated 
that H pylori eradication therapy could reverse methylation 
in patients with chronic gastritis only and may halt the pro-
cess of  gastric carcinogenesis.
Postulated mechanism of helicobacter pylori infection for 
inducing methylation 
Experimental data from in vitro studies support our con-
tention that E-cadherin methylation might be related to H 
pylori infection. El-Omar et al [29] reported that interleukin-
1β polymorphism that led to upregulation of  interleukin-
1β with H pylori infection was associated with increased 
risk of  gastric cancer. Furthermore, Hmadcha et al [30] 
found that interleukin-1β, through the production of  nitric 
oxide and the subsequent activation of  DNA methyltrans-
ferase, might induce gene methylation. It is thus possible 
that H pylori induces methylation through the production 
of  interleukin-1β and hence the downstream activation 
of  nitric oxide and DNA methyltransferase, which subse-
quently led to an increased risk of  E-cadherin methylation 
and hence gastric cancer[31].
OTHER REGULATORY MECHANISMS OF 
E-CADHERIN 
Loss of  E-cadherin function during tumor progression can 
also be caused by transcriptional repression binding to the 
CDH1-E box elements, e.g. by the repressors Snail[32,33] and 
Sip-1[34]. Tyrosine phosphorylation has also been previously 
implicated in the regulation of  cadherin function: 
RTKs, such as EGFR, c-Met and FGFR, and the non-
receptor tyrosine kinase, c-Src, phosphorylate E-cadherin, 
N-cadherin, β-catenin, -catenin and p120ctn, resulting in 
the disassembly of  the cytoplasmic adhesion complex and 
a disruption of  cadherin-mediated cell adhesion and cell 
scattering[35-37]. 
SOLUBLE E-CADHERIN
E-cadherin has a cleavage site near the transmembrane 
domain and artificially produces a soluble 80 ku amino-
terminal fragment in the culture medium upon trypsin 
digestion in the presence of  calcium[38]. This soluble 
E-cadherin fragment is considered to be a degradation 
product of  the 120 ku intact E-cadherin generated by a 
calcium-dependent proteolytic action, and can be detected 
in the protein extract of  tissue samples from peripheral 
blood and urine in normal subjects[39]. Serum soluble 
E-cadherin is reported to be increased in dermatological 
disorders (bullous pemphigoid, pemphigus vulgaris, 
psoriasis vulgaris), multi-organ failure, and various tumors 
like bladder cancer, prostate cancer, lung cancer and 
gastric cancer[39-43]. The role of  soluble E-cadherin and its 
biological significance is still, at present, unclear. Recent 
studies indicate that, in inflammatory condition, serum 
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soluble E-cadherin is induced by inflammatory mediators 
and cytokines[44]; whereas in cancerous diseases, soluble 
E-cadherin is increased by cleavage of  tissue E-cadherin 
due to overexpressed proteases[45]. The potential of  soluble 
E-cadherin to be a prognostic marker in cancerous diseases 
has been shown in bladder cancer[40] and gastric cancer[46]. 
We have examined the potential clinical application 
of  E-cadherin. We first studied the correlation between 
E-cadher in immunosta in ing express ion and the 
concentration in sera[47]. We found that normal strong 
membranous staining, e.g. in normal gastric epithelium, 
was associated with low levels of  serum soluble 
E-cadherin, but a partially reduced; cytoplasmic staining, 
e.g. in intestinal type of  gastric cancer, was associated 
with high levels; whereas complete absence of  staining, 
e.g. in diffuse type of  gastric cancer, was associated 
with low levels of  soluble E-cadherin. We also found 
that soluble E-cadherin may be a potentially useful 
prognostic marker. High levels of  soluble E-cadherin 
correlated with the depth of  tumor invasion, as well as 
inoperability[48]. More importantly, levels higher than 10 
000 ng/mL predicts survival less than 3 years in more 
than 90% of  patients[47]. Currently, we are investigating 
the use of  post-operative soluble E-cadherin levels to 
predict tumor recurrence in patients who have received 
curative surgery for gastric cancer.
CONCLUSION
Being an adhesion molecule, E-cadherin plays an impor-
tant role in invasion and metastasis in almost all kinds of  
epithelial malignancies, and hence is named invasion sup-
pressor gene. However, recent studies have shown that 
E-cadherin actually plays an early and important role in 
carcinogenesis and acts as a tumor suppressor gene, partic-
ularly in gastric cancer. Further thorough understanding of  
the role of  E-cadherin and its association with extracellular 
environment and intracellular functions will be extremely 
important. Potentially, reversing methylation at E-cadherin 
in the gastric epithelium in patients with H pylori infection 
may halt the process of  future development of  gastric 
cancer. In addition, soluble E-cadherin may be a useful 
prognostic marker for gastric cancer.
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